Literature DB >> 23713053

Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report.

H H van der Zee1, E P Prens.   

Abstract

Hidradenitis suppurativa (HS) is an inflammatory, debilitating skin disease of follicular origin, characterized by painful deep-seated, inflamed lesions in mainly the inverse areas of the body. HS is notoriously difficult to treat and especially severe disease is often resistant to therapy. New therapeutic options are therefore highly needed. Elevated levels of IL-1 have been demonstrated in HS lesions. Here we report for the first time on the sequential treatment with anakinra (an IL-1 receptor antagonist) and golimumab (a TNF-α-neutralizing antibody) of a patient with severe HS and with comorbid psoriatic arthritis. Although adalimumab and golimumab were efficacious in improving arthritis complaints, both failed in improving the severe HS of our patient. Eventually the patient underwent radical excision of the inflammatory lesions and fistulas.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23713053     DOI: 10.1159/000343221

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  14 in total

Review 1.  [Hidradenitis suppurativa/acne inversa: An update].

Authors:  J Kirschke; S Hessam; F G Bechara
Journal:  Hautarzt       Date:  2015-06       Impact factor: 0.751

Review 2.  An Update on Medical Treatment Options for Hidradenitis Suppurativa.

Authors:  I E Deckers; E P Prens
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

3.  Diagnoses of Hidradenitis Suppurativa in the United States, 1979-2012.

Authors:  Kathleen McMillan
Journal:  Skin Appendage Disord       Date:  2015-09-18

Review 4.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 5.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

Review 6.  Update on hidradenitis suppurativa: connecting the tracts.

Authors:  Liza Gill; Melissa Williams; Iltefat Hamzavi
Journal:  F1000Prime Rep       Date:  2014-12-01

Review 7.  Review of Current Immunologic Therapies for Hidradenitis Suppurativa.

Authors:  Victoria K Shanmugam; Nadia Meher Zaman; Sean McNish; Faye N Hant
Journal:  Int J Rheumatol       Date:  2017-08-20

Review 8.  Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.

Authors:  Gabriele Fenini; Emmanuel Contassot; Lars E French
Journal:  Front Pharmacol       Date:  2017-05-22       Impact factor: 5.810

Review 9.  Systematic review of immunomodulatory therapies for hidradenitis suppurativa.

Authors:  Shi Yu Derek Lim; Hazel H Oon
Journal:  Biologics       Date:  2019-05-13

Review 10.  Acne inversa: difficulties in diagnostics and therapy.

Authors:  Beata Bergler-Czop; Karolina Hadasik; Ligia Brzezińska-Wcisło
Journal:  Postepy Dermatol Alergol       Date:  2015-08-12       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.